We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Origenis Extends Collaboration and Licensing Agreement with Major Pharmaceutical Company
News

Origenis Extends Collaboration and Licensing Agreement with Major Pharmaceutical Company

Origenis Extends Collaboration and Licensing Agreement with Major Pharmaceutical Company
News

Origenis Extends Collaboration and Licensing Agreement with Major Pharmaceutical Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Origenis Extends Collaboration and Licensing Agreement with Major Pharmaceutical Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The alliance combines Origenis' capabilities in compound design, chemical synthesis, and screening with the collaborator’s applied biology, pharmacology, and development expertise in therapeutics.

During the long standing collaboration, Origenis successfully employed its proprietary small molecule discovery platform MOREsystem® to design, synthesize, and characterize novel molecules acting against different targets. Under the extended agreement, Origenis will deliver development candidates with defined properties for certain targets.

Dr. Michael Thormann, Managing Director at Origenis said: “This new agreement underlines the quality of the compounds transferred in the past and the power of our technology platform as well as our interdisciplinary approach and expertise applied to development compounds and commitment of our company in the small molecule drug sector.”

Under the terms of the agreement, the collaborator will receive rights to develop products against defined molecular targets for any indication. Origenis will receive research payments and is eligible for certain development milestones and also royalties on sales.

Advertisement